Información de la revista
Vol. 43. Núm. 1.
Páginas 19-23 (enero - febrero 2019)
Visitas
968
Vol. 43. Núm. 1.
Páginas 19-23 (enero - febrero 2019)
ORIGINALS
Acceso a texto completo
Medicines under additional monitoring in the European Union
Medicamentos sujetos a seguimiento adicional en la Unión Europea
Visitas
968
Gloria Manso1, Fernando Neira1, Sandra Ortega1, Luis H. Martín2, María Sáinz2, Esther Salgueiro1,
Autor para correspondencia
salgueiroesther@uniovi.es

Author of correspondence Esther Salgueiro Vázquez, Departamento de Medicina. Área de Farmacología. Universidad de Oviedo. C/ Julián Clavería 6, 33006 Oviedo. España.
1 Departamento de Medicina, Área de Farmacología, Universidad de Oviedo, Oviedo. Spain.
2 Centro de Estudios sobre Seguridad de Medicamentos (CESME), Universidad de Valladolid, Valladolid. Spain.
Este artículo ha recibido
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Figuras (1)
Tablas (3)
Table 1. Characteristics of the medicines under additional monitoring (List EMA/245297/2013 Rev.41)
Tablas
Table 2. Temporal evolution of the criteria used to assign medicines under additional monitoring
Tablas
Table 3. Safety information notes on medicines under additional monitoring issued by the Spanish Agency of Medicines and Medical Devices until January 23, 2017
Tablas
Mostrar másMostrar menos
Abstract
Objective

The objective of this study was to analyse the characteristics of medicines subject to additional monitoring. We assessed the following aspects: the criteria applied to approve a medicine as being subject to additional monitoring; the authorized dispensing conditions; the pharmacological groups to which they belong; and their post-authorisation safety.

Method

We analysed the list published by the European Medicines Agency in January 2017 (EMA/245297/2013 Rev.41). Information for the analysis was obtained from the web sites of the European Medicines Agency and the Spanish Agency of Medicines and Medical Devices.

Results

We assessed 316 medicines subject to additional monitoring. The most common criterion used to assign a medicine as being subject to additional monitoring was it being a new active substance (n = 197 [62.3%]). Other common criteria were requiring a post-authorisation safety study (n = 52 [16.5%]) and being a biologic medicine but not a new active substance (n = 49 [15.5%]). Regarding dispensing conditions, nearly 66% of these medicines were authorized under restricted conditions. Until January 2017, the Spanish Agency of Medicines and Medical Device published 14 safety reports related to medicines subject to additional monitoring.

Conclusions

The group of medicines subject to additional monitoring mainly includes new active substances. The most common pharmacological group is antineoplastic and immunomodulating agents. The post-authorisation safety study has already produced information published by the Spanish Agency of Medicines and Medical Devices.

KEYWORDS:
Drug monitoring
European Union
Pharmacovigilance
Biosimilar pharmaceuticals
Mandatory reporting
Resumen
Objetivo

El objetivo de nuestro estudio fue analizar las características de los medicamentos sujetos a seguimiento adicional. Para ello, estudiamos: los criterios aplicados para su designación, los criterios de dispensación autorizados, los grupos farmacológicos a los que pertenecen y su seguridad postcomercialización.

Método

Se analizó la lista publicada por la Agencia Europea de Medicamentos en enero de 2017 (EMA/245297/2013 Rev.41). La información para el análisis se extrajo de las páginas web de la Agencia Europea de Medicamentos y la Agencia Española de Medicamentos y Productos Sanitarios.

Resultados

Se estudiaron 316 medicamentos sujetos a seguimiento adicional. El criterio de designación más común fue ser un nuevo principio activo (n = 197 [62,3%]). Otros criterios de designación comunes fueron: requerir un estudio postautorización de seguridad (n = 52 [16,5%]) y ser un medicamento biológico, aunque no un nuevo principio activo (n = 49 [15,5%]). Con respecto a las condiciones de dispensación, casi el 66% de estos medicamentos se autorizaron con criterios de dispensación restringidos. Hasta enero de 2017, la Agencia Española de Medicamentos y Productos Sanitarios había publicado 14 notas informativas de seguridad referidas a los medicamentos sujetos a seguimiento adicional.

Conclusiones

Los medicamentos sujetos a seguimiento adicional incluyen mayoritariamente nuevas sustancias activas. El grupo farmacológico más frecuente es el de los fármacos antineoplásicos e inmunomodulado-res. La revisión postcomercialización de su seguridad ha generado ya alguna información publicada por la Agencia Española de Medicamentos y Productos Sanitarios.

PALABRAS CLAVE:
Monitorización de medicamentos
Unión Europea
Farmacovigilancia
Biosimilares farmacéuticos
Notificación obligatoria
Texto completo
Introduction

In 2012, a new measure on the additional monitoring of specific medicines was introduced in the European legislation on pharmacovigilance1,2. This measure affects medicines authorized by the European Medicines Agency (EMA) in the European Union that require particularly rigorous and intensive monitoring by the health authorities.

Medicines Under Additional Monitoring (MUAM) are identified with an inverted black triangle (▼). Additional monitoring status is applied to a medicine in the following cases3: 1) it contains a new active substance that was authorized in the European Union after January 1, 2011; 2) it is a biological medicine that was authorized in the European Union after January 1, 2011; 3) it has been given conditional authorization, for which the Marketing Authorisation Holder (MAH) must provide additional data; 4) it has been given conditional authorisation under exceptional circumstances (when there are specific reasons why the MAH cannot provide a comprehensive dataset and must complete the information after authorisation); and 5) it is a medicine for which the MAH must conduct post-authorization safety studies (PASS). Currently, MUAMs remain subject to additional monitoring for five years after their authorisation or until the EMA Pharmacovigilance Risk Assessment Committee (PRAC) considers that it is safe to withdraw them from the list of MUAMs.

In April 2013, the EMA published the first MUAM list, which is reviewed monthly by the PRAC3. In 2013, the Spanish Agency of Medicines and Medical Devices (AEMPS in Spanish) published two information notes on this measure that were aimed at healthcare professionals4 and citizens5, respectively. In addition, some therapeutic and pharmacovigilance bulletins have reported on the MUAM concept and procedure6–8, and some published articles have addressed safety and other aspects related to the use of specific MUAMs9–13.

The overall objective of this study was to analyse the characteristics of MUAMs. Specifically, we assessed the following aspects: the criteria applied to approve a medicine as a MUAM; the dispensing criteria assigned to these medicines; the pharmacological groups to which they belong; and their post-authorisation safety.

Methods

We conducted a descriptive analysis of the EMA MUAM list, which was updated on January 23, 201714. Medicines whose authorization had been revoked or suspended were excluded. Medicines authorized between January 23, 2012 and January 23, 2017 were considered to be new active substances. The following websites were used as information sources: 1) the EMA14 (list of MUAMs, authorization dates and Summary of Product Characteristics, and information related to the authorization criteria); 2) the AEMPS Medicine Information Center15 (conditions for dispensing medicines); and 3) the Norwegian Institute of Public Health, WHO Collaborating Centre for Drug Statistics Methodology16 (Anatomical-Therapeutic-Chemical [ATC] classification code corresponding to each active principle).

Each MUAM was analysed according to whether: 1) it was a new active substance; 2) it was a biological drug, biosimilar or otherwise, excluding those already included as new active substances; and 3) other criteria had been applied to approve the medicine as a MUAM (conditional authorization, authorization in exceptional circumstances, PASS). We also analysed the following aspects: 1) the temporal evolution (2013-2016) of the MUAM assignment criteria; 2) assignment as an “orphan drug” or otherwise; 3) the authorized dispensing conditions, classified as “unrestricted” (MSMP: medicines subject to medical prescription) and “restricted” (DH: hospital diagnosis and H: hospital use); and 4) the pharmacological group to which they belong: 1st level (organ and system) and 2nd level (therapeutic subgroup) of the ATC classification corresponding to each active principle.

For the purposes of the PASS, we reviewed the information notes on MUAM safety published by the AEMPS until January 23, 2017, and analysed the reasons for issuing the information note. This information was classified according to its content: 1) RBR: results of the risk/benefit analysis of the medicine; 2) CDC: changes in the dispensing criteria; 3) NCI: new contraindications; 4) RU: restrictions on use; 5) SAI: safety information.

Data on each variable defined in the study were cleaned and statistical analyses were conducted using the IBM SPSS Statistics software package version 24.0 (IBM Corp, Armonk, New York). The majority of the results are expressed as absolute (n) and relative frequencies (%).

Results

The MUAM list (EMA/245297/2013 Rev.41) was updated on January 23, 2017 and included 320 medicines. Of these, 4 were excluded because their marketing authorization was revoked or suspended after they had been included in the list. Of the 316 remaining MUAMs, 197 (62.3%) contained new active substances (Table 1). Other inclusion criteria were as follows: the need for a PASS (n = 52 [16.5%]); and being a biological medicine, but not a new active ingredient (n = 49 [15.5%]). Of the total of 197 MUAMs containing new active substances, at least 1 additional criterion was applied to 55 (24.9%) of them. Overall, almost 66% of the MUAMs (n = 207 [65.3%]) were authorized under restricted dispensing conditions, with hospital use being the most common dispensing criterion (n = 143 [45.1%]).

Table 1.

Characteristics of the medicines under additional monitoring (List EMA/245297/2013 Rev.41)

A. Criteria for assignment as MUAM 
New active substance  142  44.9 
New active substance + PASS  29  9.2 
New active substance + conditional authorization  20  6.3 
New active substance + authorization in exceptional circumstances  1.9 
Other criteria  119  37.7 
PASS  52  16.5 
Biological medicine  49  15.5 
Biosimilar  13  4.1 
Not biosimilar  36  11.4 
Authorization in exceptional circumstances  16  5.1 
Conditional authorization  0.3 
Biological medicine + authorization in exceptional circumstances  0.3 
Total  316  100 
B. Authorized dispensing conditions     
Restricted dispensing  207  65.3 
Medicines for hospital use  143  45.1 
Diagnostic medicines for hospital use  64  20.2 
Normal dispensing (not restricted)  110  34.7 
Total  317  100.0 

MUAM: medicines under additional monitoring; PASS: post-authorisation safety study.

Of the 197 MUAMs containing new active substances, 53 (26.9%) were new biological active substances and 47 (23.9%) were orphan medicines (18 biological orphan medicines and 29 non-biological orphan medicines). The new active substances of the MUAMs analysed mainly belonged to the 1st level of the ATC classification (anatomical main group) (Figure 1): antineoplastic and immunomodulatory agents (L) (n = 59 [29.9%]), antiinfective agents for systemic use (J) (n = 32 [16.2%]); and drugs for metabolism and the alimentary tract (A) (n = 30 [15.2%]). Within the group of antineoplastic and immunomodulatory agents, the most common pharmacological group were tyrosine kinase inhibitors (n = 24 [12.2%]).

Figure 1.

Anatomical-therapeutics-chemistry (ATC) classification of medicines under additional monitoring with new active substances in their composition.

(0.19MB).

The analysis of the temporal evolution of the criteria used to assign medicines as MUAMs over the period 2013 to 2016 showed the following: 1) the criterion “new active substance” applied to at least half of the medicines assigned as MUAMs each year during the study period; 2) the criterion “biological medicine” but not a new active substance applied to 32.3% (its highest value) of the medicines assigned as MUAMs in 2016; 3) the criteria “conditional authorization” and “authorization in exceptional circumstances” applied to less than 3% of MUAMs in the period 2014 to 2016; and 4) there was a decrease in the number of medicines fulfilling the “PASS” criterion in 2015 and 2016 (only 3.2% of the MUAMs in 2016) (Table 2).

Table 2.

Temporal evolution of the criteria used to assign medicines under additional monitoring

Criteria  2013201420152016
  n  %  n  %  n  %  n  % 
New active substance  50  49.5  36  58.1  52  73.2  40  64.5 
Biological medicine  14  13.9  8.1  11.3  20  32.3 
CA or AEC  13  12.9  1.6  2.8 
PASS  24  23.7  20  32.2  12.7  3.2 
Total  101  100.0  62  100.0  71  100.0  62  100.0 

AEC: authorization in exceptional circumstances; CA: conditional authorization; PASS: post-authorization safety study.

From the time of publication of the first MUAM safety information note on June 3, 2013 (MUH [FV], 13/2013) to January 23, 2017, the AEMPS published 68 safety information notes, of which 2 explained the concept of MUAMs to healthcare professionals and citizens and 14 (20.6%) referred to some aspect related to the safety of the MUAMs involved (Table 3). These 14 informative notes referred to the following aspects: new information on safety (7), restrictions on the use of the drug (3), the results of the risk/benefit analysis (2), changes in the medicine dispensing conditions (1), and new contraindications (1). Three of the informative notes referred to strontium ranelate (change in its dispensing conditions to a diagnostic drug for hospital use) and 2 referred to idelalisib (measures to prevent the risk of severe infection). These 2 active substances were the ones more often referred to in the notes.

Table 3.

Safety information notes on medicines under additional monitoring issued by the Spanish Agency of Medicines and Medical Devices until January 23, 2017

Reference  Active substance (trade name)  Title  Issue  Year* 
MUH (FV), 13/2013  Retigabine (▼Trobalt®)  Restricted indications after notification of cases of ocular and cutaneous pigmentation  RU  2011 
MUH (FV), 1/2014  Strontium ranelate (▼Osseor®, ▼Protelos®)  The European review suggests an unfavorable risk/benefit ratio  BBR  2004 
MUH (FV), 2/2014  Strontium ranelate (▼Osseor®, ▼Protelos®)  Restricted use  RU  2004 
MUH (FV), 9/2014  Strontium ranelate (▼Osseor®, ▼Protelos®)  Categorised as a diagnostic medicine for use in hospitals  CD  2004 
MUH (FV), 13/2014  Denosumab (Prolia®, ▼Xgeva®)  Risk of osteonecrosis of the jaw and hypocalcaemia  SEG  2010 
MUH (FV), 5/2015  Pomalidomide (▼Imnovid®)  Risk of severe liver toxicity, heart failure, and interstitial lung disease  SEG  2013 
MUH (FV), 6/2015  ▼Harvoni®, ▼Sovaldi®, ▼Daklinza®, associated with amiodarone  Risk of severe bradycardia and cardiac block associated with its administration  SEG  2014 
MUH (FV), 12/2015  Fingolimod (▼Gilenya®)  Recommendations on risks related to its immunosuppressive effect  SEG  2011 
MUH (FV), 13/2015  ▼Viekirax®, ▼Exviera® (in combination)  Risk of decompensation and liver failure after administration  SEG  2015 
MUH (FV), 1/2016  Natalizumab (▼Tysabri®)  New recommendations to minimize the risk of progressive multifocal leukoencephalopathy  SEG  2006 
MUH (FV), 4/2016  Aflibercept (▼Zaltrap®)  Risk of osteonecrosis of the jaw associated with its administration  SEG  2013 
MUH (FV), 5/2016  Idelalisib (▼Zydelig®)  Temporary use restrictions to prevent severe infection while its risk/benefit ratio is revaluated in Europe  RU  2014 
MUH (FV), 12/2016  Riociguat (▼Adempas®)  Contraindicated in patients with pulmonary hypertension associated with idiopathic interstitial pneumonias (HP-NII)  CNT  2014 
MUH (FV), 14/2016  Idelalisib (▼Zydelig®)  Conclusions of the European reevaluation of its risk/benefit ratio  BBR  2014 

BBR: risk/benefit ratio; CD: dispensing criteria; CNT: contraindications; FV: pharmacovigilance; MUH: medicines for human use; RU: restricted use; SEG: safety.

*

Year of authorization.

Discussion

The inverted black triangle symbol (▼) used in the United Kingdom to identify new active substances17 was adopted by the EMA to identify

MUAMs. After the adoption of the European regulation, the AEMPS eliminated the yellow triangle (▲) that had been used in Spain to indicate new active substances. Assigning the inverted black triangle (▼) to a medicine does not mean that it is unsafe. Its purpose is to encourage health professio-nals18 and citizens19 to report suspected adverse reactions associated with the medicine, thus facilitating the benefit-risk analysis.

The present study found that almost 66% of MUAMs contained new active substances. Thus, there is a need to complete the information on their safety20. The percentage of MUAMs with new active substances remained equal to or greater than 50% during each year of the study period. These new active substances mainly belonged to the group of antineoplastic and immunomodulatory medicines. Among these medicines, tyrosine kinase inhibitors deserve special mention due to the frequency of new active subs-tances21,22.

One-third of the MUAMs were biological medicines, equally divided into new active substances and 13 biosimilars. Biological medicines include proteins (e.g. peptide hormones), enzymes produced naturally by the human body, monoclonal antibodies, and blood products. They also include immunological medicines (e.g. serums, vaccines, and allergens), and advanced technological products (e.g. gene and cell therapy products)23–25. Due to their chemical characteristics and safety profiles26,27, pharmacovigilance plays a critical role in the setting of biological medicines28.

A high percentage of MUAMs were subject to restricted dispensing (mainly for hospital use) and almost all orphan medicines were under restricted dispensing. Orphan medicines are used to treat rare diseases that affect only a small number of patients (< 5/10 000 individuals in the EU or < 200 000 individuals in the USA)29. Approximately 20% of MUAMs were authorized as orphan medicines, of which more than half were new active substances that mainly comprised antineoplastic and immunomodulatory agents.

Prior to 2017, the AEMPS had published 14 safety information notes on medicines identified with the inverted black triangle (▼)30. All of these notes highlighted the relevance of the additional monitoring of these medicines and the priority notification of suspected adverse reactions.

The main limitation of this study is related to dynamic changes to the EMA MUAM list, which is updated every month. This limitation was compensated for by the high number of MUAMs studied, given that all MUAMs authorized from the beginning of this procedure in 2013 to January 2017 were analysed. The main strength of this study is its usefulness to became known MUAM among health professionals. We propose that the MUAM inverted black triangle (▼) should be incorporated in prescription and electronic dispensing systems to facilitate its identification by health care staff.

In conclusion, the MUAMs mainly included new active substances, which, for reasons of safety or conditions of authorization, require close and careful post-authorisation monitoring. The majority of the new substances belong to the antineoplastic and immunomodulatory group of medicines. The updated PASS has already provided new information that has been published in the informative notes of the AEMPS. Knowledge of these medicines and their identification symbol (▼) should facilitate early risk/benefit analyses.

Funding

No funding.

Conflict of interests

No conflict of interests.

Contribution to the scientific literature.

Common criteria used to designate a medicine as being under additional monitoring are that it contains a new active substance, that it requires post-authorisation safety studies or that it is a biological medicinal product. These medicines are commonly used in cancer and immune processes, and their dispensing criteria are often restricted. Post-authorisation monitoring has already generated additional information to ensure their safer use.

Bibliografía
[1]
Regulation (EU) No 1235/2010 of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance of medicinal products for human use, Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, and Regulation (EC) No 1394/2007 on advanced therapy medicinal products. Text with EEA relevance Official Journal European Union, 348/1, (31 december 2010) [citado 13/06/2018]; Disponible en: https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/-eg_2010_1235/reg_2010_1235_en.pdf
[2]
Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance, Directive 2001/83/EC on the Community code relating to medicinal products for human use. Text with EEA -elevance Official Journal European Union, 348/74, (31 december 2010) [citado 13/06/2018]; Disponible en: https://ec.europa.eu/health//sites/health/files/files/eudralex/vol-1/dir_2010_84/dir_2010_84_en.pdf
[3]
European Medicines Agency. Medicines under additional monitoring 2013 [citado 13/06/2018]. Disponible en: http://www.ema.europa.eu/docs/es_ES/document_library/Other/2013/04/WC500142430.pdf
[4]
Medicamentos sometidos a seguimiento adicional de su seguridad 2013 (Y)-NIMUH_FV_25-2013-seguimiento-adicional.pdf [citado 13/06(2018]. Disponible en: https://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2013/docs/N I-MUH_FV_25-2013-seguimiento-adicional.pdf
[5]
Medicamentos sometidos a seguimiento adicional de su seguridad 2013 (Y)-NIMUH_FV_26-2013-seguimiento_adicional.pdf [citado 13/06/2018]. Disponible en: https://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/ciudadanos/2013/docs/NI-MUH_FV_26-2013-seguimiento_adicional.pdf
[6]
CADIME (Centro Andaluz de Documentación e Información de Medicamentos. Primer listado de medicamentos sujetos a seguimiento adicional. 2017 [citado 13/06/2018]. Disponible en: http://www.cadime.es/generate_pdf.cfm
[7]
Boletín de Farmacovigilancia del País Vasco. Medicamentos sujetos a seguimiento adicional: Triángulo negro. 2013 [citado 13/06/2018]. Disponible en: https://www.osakidetza.euskadi.eus/contenidos/informacion/boletines_farmacovigilancia/es_def/adjuntos/Boletin_36.pdf
[8]
Butlletí de Farmacovigilancia de Cataluña. 2013 [citado 13/06/2018]. Disponible en: http://medicaments.gencat.cat/web/.content/minisite/medicaments/professionals/6_publicacions/butlletins/boletin_farmacovigilancia/documents/arxius/bfv_v11_n5e.pdf
[9]
Carter NJ .
Inhaled glycopyrronium bromide: a review of its use in patients with moderate to severe chronic obstructive pulmonary disease.
[10]
Sportiello L , Rafaniello C , Scavone C , Vitale C , Rossi F , Capuano A .
The importance of Pharmacovigilance for the drug safety: Focus on cardiovascular profile of incretinbased therapy.
[11]
Caraci F , Leggio GM , Salomone S , Drago F .
New drugs in psychiatry: focus on new pharmacological targets.
[12]
Cejalvo MJ , de la Rubia J .
Which therapies will move to the front line for multiple myeloma?.
[13]
Kroschinsky F , Stölzel F , von Bonin S , Beutel G , Kochanek M , Kiehl M , et al.
New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management.
[14]
European Medicines Agency. List of medicines under additional monitoring citado 13/06/2018]. Disponible en: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp∣=WC0b01ac058067c852
[15]
AEMPS. Centro de Información online de Medicamentos de la AEMPS (CIMA). Buscador principal [citado 13/06/2018]. Disponible en: https://www.aemps.gob.es/cima/fichasTecnicas.do?metodo=detalleForm
[16]
Norwegian Institute for Public Health. WHO Collaborating Centre for Drugs Statistics Methodology. ATC Classification [citado 13/06/2018]. Disponible en: https://www.whocc.no/atc_ddd_index/
[17]
Martin RM , Kapoor KV , Wilton LV , Mann RD .
Underreporting of suspected adverse drug reactions to newly marketed (“black triangle”) drugs in general practice: observational study.
[18]
Carvajal A. Los nuevos desafíos de la farmacovigilancia en España. En Manso G, Hidalgo A, Carvajal A, de Bajo FJ (eds.). Los primeros 25 años del Sistema Español de Farmacovigilancia de Medicamentos de Uso Humano. Universidad de Oviedo; 2010 p.81-92 [citado 13/06/2018]. Disponible en: https://www.unioviedo.es/gaife/documentos/libro25aniversario/Capitulos/Capitulo_06.pdf
[19]
Salgueiro ME , Jimeno FJ , Aguirre C , García M , Ordóñez L , Manso G .
[Direct reporting by patients of adverse drug reactions in Spain].
[20]
Plessis L , Gómez A , García N , Cereza G , Figueras A .
Lack of essential information in spontaneous reports of adverse drug reactions in Catalonia-a restraint to the potentiality for signal detection.
[21]
Ellis LM , Hicklin DJ .
Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology.
Clin Cancer Res Off J Am Assoc Cancer Res, 15 (2009), pp. 7471-7478
[22]
Toffalini F , Demoulin JB .
New insights into the mechanisms of hematopoietic cel transformation by activated receptor tyrosine kinases.
[23]
Boletin Oficial del Estado, n° 177, (25 de julio de 2015). Real Decreto 1/2015, de 24 de julio, por el que se aprueba el texto refundido de la Ley de garantías y uso racional de los medicamentos y productos sanitarios [citado 13/06/2018]. Disponible en: https://www.boe.es/boe/dias/2015/07/25/pdfs/BOEA-2015-8343.pdf
[24]
Serra López-Matencio JM , Morell Baladrón A , Castañeda S .
Biosimilars: A new scenario in biologic therapies.
[25]
Bennett CL , Chen B , Hermanson T , Wyatt MD , Schulz RM , Georgantopoulos P , et al.
Regulatory and clinical considerations for biosimilar oncology drugs.
[26]
González V , Salgueiro E , Jimeno FJ , Hidalgo A , Rubio T , Manso G .
Post-marketing safety of antineoplasic monoclonal antibodies: rituximab and trastuzumab.
Pharmacoepidemiol Drug Saf, 17 (2008), pp. 714-721
[27]
Calvo B , Zuñiga L .
EU's new pharmacovigilance legislation: considerations for biosimilars.
[28]
Martos-Rosa A , Martínez-de la Plata JE , Morales-Molina JA , Fayet-Pérez A , Acosta-Robles PJ .
[Biosimilars, the journey has begun].
[29]
Franco P .
Orphan drugs: the regulatory environment.
[30]
Agencia Española de Medicamentos y Productos Sanitarios. Medicamentos de Uso Humano. Notas de seguridad. AEMPS [citado 13/06/2018]. Disponible en: https://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/home.htm
Copyright © 2019. Sociedad Española de Farmacia Hospitalaria
Descargar PDF
Idiomas
Farmacia Hospitalaria
Opciones de artículo
Herramientas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.